Is this bad news for CSL shares?

Should you be worried by this trial news?

| More on:
man with his hand on his chin wondering about the AIM share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are edging lower on Tuesday.

In morning trade, the biotherapeutics giant's shares are down 0.5% to $257.50.

What's weighing on its shares?

Today's weakness may be down to news that a competing treatment has delivered strong trial results.

Overnight, the Argenx SE (NASDAQ: ARGX) share price rocketed 28% on Wall Street after reporting positive topline data from the ADHERE study of Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Argenx said:

CIDP is a chronic, progressive autoimmune disease that can cause substantial disability in those affected, often leading to impaired ambulation or difficulty completing normal daily tasks without help. The positive ADHERE data show that VYVGART Hytrulo may represent a new patient-forward treatment option that can prevent symptom deterioration while minimizing side effects and treatment burden.

The ADHERE study is the largest clinical trial of CIDP patients to date, enrolling adults who were treatment naïve or currently on immunoglobulin therapy or corticosteroids.

Is this bad news for CSL shares?

This news could potentially be bad news for CSL and its shares due to the significant revenue it generates from its immunoglobulin therapies. In response to the trial, Goldman Sachs said:

ARGX has reported the top-line data from its ADHERE study, evaluating Vyvgart (first-in-class FcRn inhibitor) for safety and efficacy in the treatment of chronic immune demyelinating polyneuropathy (CIDP), the indication responsible for 25-35% of IG demand (IG is currently the most important protein derived from plasma fractionation, constituting 37% of CSL's FY23E revenue forecasts and 56% of growth FY23-26E).

Our Argenx analyst currently forecasts peak sales of $1,921mn/$1,248mn (unadjusted/risk-adjusted) in 2035 for Vyvgart in CIDP.

The good news is that the team at UBS don't believe that Vyvgart will have an overly large impact on CSL's revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.

As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »